{"id":"W2612554234","doi":"10.1093/annonc/mdx091.058","title":"An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Discontinuation; Lung cancer; Adverse effect; Cohort; Cancer; Phases of clinical research; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001566264,0.001818746,0.002252881,0.0004830143,0.0006610838,0.001389634,0.001302946,0.001719741,0.007580857],"category_scores_gemma":[0.001138686,0.0007483513,0.002141914,0.0003585629,0.001538402,0.00175064,0.0005095534,0.005337263,0.001895863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001653981,"about_ca_system_score_gemma":0.00168427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001394582,"about_ca_topic_score_gemma":0.003863237,"domain_scores_codex":[0.9995028,0.0002012142,0.00001953626,0.0001129179,0.00003725129,0.0001263054],"domain_scores_gemma":[0.9992761,0.0001048263,0.00009376403,0.00007064632,0.00004831537,0.0004063237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9078865,0.0258266,0.001836013,0.0005202296,0.001140592,0.0001039629,0.0001591375,0.001466837,0.009086061,0.0002127207,0.002916039,0.0488452],"study_design_scores_gemma":[0.8346844,0.1572179,0.003996807,0.00002532487,0.0003409203,0.00009452306,0.00005651048,0.0008586464,0.0009253778,0.0003280409,0.001445813,0.00002584843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893841,0.001961593,0.0005846095,0.0008090869,0.0003368449,0.002432983,0.001386721,0.0001770938,0.002926954],"genre_scores_gemma":[0.9873198,0.00117023,0.001708748,0.001255499,0.00022807,0.002327855,0.002389358,0.00005046151,0.003549905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007580857,"threshold_uncertainty_score":0.02536047,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06134044504948236,"score_gpt":0.4184753742099122,"score_spread":0.3571349291604298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}